Latest Conference Coverage

IPX203 Boosts “Good ON” Time in Parkinson Disease, Especially in Patients on Lower Dopamine Agonist Doses

Findings from a phase 3 study revealed that patients with Parkinson disease switching to IPX203 had greater benefits in good ON time when also taking lower doses of dopamine agonists.

GLP-1 Analogs Showing Broad Neuroprotective Potential Across Neurological Disorders: Paul Edison, MBBS, PhD, FRCPI

The professor of neuroscience at the Imperial College London discussed the emerging role of GLP-1 analogs as neuroprotective agents with potential benefits in neurodegenerative conditions. [WATCH TIME: 4 minutes]

CGRP Therapies as Potential First-Line Migraine Preventive Treatment: Andrew Charles, MD

The director of the UCLA Goldberg Migraine Program discussed the advantages, evidence base, and evolving payor support for CGRP-targeting therapies as potentially a first-line option in migraine prevention. [WATCH TIME: 5 minutes]

Aggressive Blood Pressure Lowering for Intracerebral Hemorrhage Management: Chitra Venkatasubramanian, MBBS, MD, MSc, FNCS

The clinical professor of stroke neurology and neurocritical care at Stanford University advocated for early and intensive blood pressure reduction in patients with intracerebral hemorrhage to limit hematoma expansion and improve outcomes. [WATCH TIME: 5 minutes]

Newly Launched Phase 4 ENABLE Trial to Test Real-World Efficacy of Ublituximab in Relapsing Multiple Sclerosis

The ENABLE phase 4 study will evaluate the real-world safety, efficacy, and patient experience of ublituximab in relapsing multiple sclerosis over a 96-week period.

Complement-Targeting Agent ANX005 Demonstrates Therapeutic Efficacy in Phase 3 Study of Guillain-Barré Syndrome

Presented at the 2025 AAN Annual Meeting, findings from a phase 3 study showed that a single 30 mg/kg dose of ANX005 significantly improved health outcomes in Guillain-Barré syndrome, with benefits seen as early as week 1 and sustained over 6 months.

Post Hoc Analysis of ADVANCE Trial Reveals Atogepant Improves Functional Outcomes in Migraine

Findings showed that atogepant 60 mg once daily demonstrated significant improvements in functional outcomes for patients with episodic migraine, compared with placebo, over 12 weeks.

Two-Year Open-Label Data Highlight Frexalimab’s Impact on Disease Activity in Relapsing Multiple Sclerosis

Long-term data from a phase 2 study extension suggest that frexalimab, a CD40L inhibitor, maintains disease control and is well-tolerated in relapsing multiple sclerosis, reinforcing its potential as a next-generation treatment.

The Evolving and Emerging Role of Plasma Biomarkers in Diagnosing and Monitoring Alzheimer Disease

Inge Verberk, PhD, a research associate at the Amsterdam University Medical Center, sat down at AD/PD 2025 to discuss changes in Alzheimer trials, the emergence of plasma biomarkers, and deciphering which biomarkers are of utmost importance.

Study Reveals Impact of Early Adversity on Coping, Mental Health, and Cognition

A recent large-scale analysis presented at the 2025 AD/PD Conference highlighted the role of coping strategies in mitigating negative outcomes.

Baseline Analysis of MINDFuL Trial Highlights Screening Success of Enrolling Patients With Immune Dysfunction

Data suggests that immune dysfunction biomarkers do not pose a major barrier to patient enrollment in Alzheimer’s research, as most patients meeting general AD criteria also qualified under immune dysfunction criteria.

Novel IVD Tool for Rapid APOE Genotyping May Aid in Alzheimer Disease Risk Stratification

A recent poster presentation at the 2025 AD/PD conference revealed that a novel assay could provide absolute allelic discrimination for APOE genotyping, supporting precision medicine in AD treatment.

Sweden Analysis Reveals Key Lifestyle and Socioeconomic Factors Driving Cognitive Decline

An analysis of the Gothenburg Mild Cognitive Impairment Study presented at the 2025 AD/PD Conference reported that lifestyle and socioeconomic factors could significantly influence the risk of developing cognitive diseases.

Survey Study Aims to Assess Germany’s Readiness for Early Alzheimer Diagnosis Using Biomarkers

A new survey study will assess how well German memory clinics and specialists are equipped to provide early and accurate Alzheimer diagnoses using biomarker-based methods.

Cognito’s Gamma Sensory Stimulation Leads to Preserved Corpus Callosum Structure in Alzheimer Disease

The Spectris device demonstrated preserved corpus callosum structure and correlated sensory-evoked gamma oscillations in patients with Alzheimer disease, highlighting its potential neuroprotective effects.

Beyond CSF: Quanterix’s Simoa Platform Brings Blood-Based Biomarkers to the Forefront

Mark Roskey, PhD, chief scientific officer at Quanterix, provided clinical insight on the function of the company’s Simoa technology and the incorporation of various biomarkers to aid in the diagnosis of Alzheimer disease.

Assessing Investigational CT1812’s Impact on Tau, Amyloid, and Neurodegeneration: Mary Hamby, PhD

The vice president of research at Cognition Therapeutics gave clinical insight on several new analyses covering CT1812, an orally delivered small molecule oligomer antagonist, in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]

Patient-Informed Phase 2 ATLANTIS Study Tests Selective D1PAM Agent Glovadalen for Parkinson Disease

Presented at the 2025 AD/PD Conference, the study incorporates patient engagement in its design and implementation, focusing on optimizing study accessibility, reducing burden, and evaluating glovadalen’s potential as an adjunctive treatment for PD.

Vibrotactile Stimulation Device Shows Promise in Addressing Gait Issues in Parkinson Disease

A pilot study, presented at the 2025 AD/PD conference, evaluating the CUE1 device suggests it may help improve motor symptoms and reduce fall risk in patients with Parkinson disease.

Discovering Role of Complement Activation in ARIA Risk Amid Fluid Treatment Landscape: Cynthia Lemere, PhD

The professor of neurology at Brigham and Women’s Hospital provided clinical insights on her presentation at AD/PD 2025 focusing on the emerging research surrounding complement activation and its influence on amyloid-related imaging abnormalities. [WATCH TIME: 7 minutes]

Remote Screening for Early Alzheimer Holds Promise Amid Key Challenges

Recently presented at the 2025 AD/PD Conference, the REAL AD study aims to assess the feasibility of blood biomarkers and digital cognitive testing for early detection of Alzheimer disease.

Alzheimer Biomarkers pTau217 and pTau181 Show High Group-Level Correlation With Trial End Points

Investigators at AD/PD 2025 presented new data showing that changes in plasma p-tau217 and p-tau181 closely correlate with clinical outcomes in anti-amyloid therapy trials for Alzheimer disease.

Overviewing Design and Topline Data From Phase 3 APOLLOE4 Study of Valiltramiprosate in Alzheimer Disease: Anton Porsteinsson, MD

The director of the Alzheimer’s Disease Care, Research, and Education Program at the University of Rochester provided clinical insight on a pivotal trial testing a novel therapeutic in patients with Alzheimer disease who are carriers of APOE4/4. [WATCH TIME: 7 minutes]

NeuroVoices: Cynthia Lemere, PhD, on Exploring the Role of Complement in ARIA and CAA

The professor of neurology at Brigham and Women’s Hospital gave clinical insights on the therapeutic potential of targeting compliment as a way to mitigate risk for amyloid-related imaging abnormalities from antiamyloid therapies.

Genetic Risk Factors Influence Age at Onset in Autosomal Dominant Alzheimer Disease

A recent study presented at the 2025 AD/PD Conference identified key modifiers of Alzheimer disease onset in amyloid precursor protein duplication carriers.

Xanamem Shows Potential in Slowing Alzheimer Progression in Patients With Elevated Plasma pTau181

A phase 2a biomarker trial of xanamem presented at AD/PD 2025 suggests the drug may help slow clinical decline in patients with Alzheimer who have elevated levels of plasma pTau181.

Therapeutic Potential of Silmitasertib Observed in Huntington Disease Mouse Model

A recent study reported that silmitasertib, an investigational drug currently in development for cancer, may help reduce motor deficits and neuropathology in a Huntington disease.

Valiltramiprosate Demonstrates Greater Promise in Earlier Stages of Alzheimer Disease, Phase 3 APOLLOE4 Study Shows

Although valiltramiprosate failed to distinguish itself from placebo on the primary end point, the drug performed significantly better among mild MCI participants vs those with mild Alzheimer disease.

Higher CSF Aß42/Total Tau Ratio Associated With Increased ARIA Risk in Lecanemab

Research suggests that CSF ATI ratios could serve as a biomarker for identifying patients with Alzheimer disease at higher risk of ARIA during lecanemab treatment, aiding in safer patient management.

Exploring Multimodal Approaches to Neural Regeneration: Kuldip Dave, PhD

The senior vice president of research at The ALS Association talked about a multidisciplinary session presented at the 2025 MDA Conference that highlighted diverse strategies for neural repair, from pharmacological targets to noninvasive brain stimulation. [WATCH TIME: 6 minutes]